Augtyro(repotrectinib,瑞普替尼)

[Augtyro drug interaction]  

Strong and moderate CYP3A inhibitors: Avoid simultaneous use.

 P-gp inhibitors: avoid simultaneous use.

 Strong and moderate CYP3A inducers: Avoid simultaneous use.  

Some CYP3A substrates: Avoid using with CYP3A substrates at the same time, in which the smallest concentration change may lead to reduced efficacy.  

Hormone contraceptives: Avoid simultaneous use.

[Augtyro warnings and precautions]  

Central nervous system (CNS) effects: It can cause adverse reactions of the central nervous system, including dizziness, ataxia and cognitive impairment. Stop taking it, and then recover with the same or reduced dose after improvement, or permanently stop using Augtyro according to the severity.

Interstitial lung disease (ILD)/ pneumonia: Monitor patients for new or worsening lung symptoms to indicate ILD/ pneumonia. Patients with suspected ILD/ pneumonia should stop taking drugs immediately, and if diagnosed with ILD/ pneumonia, they should stop taking drugs permanently.  

Hepatotoxicity: In the first month of treatment, the liver function was monitored every two weeks, and then monitored according to clinical indications. According to the severity, stop taking medicine, then continue taking medicine at the same or reduced dose, or stop taking medicine permanently.  

Myodynia with elevated creatine phosphokinase (CPK): During the treatment, the serum CPK level of patients who reported unexplained muscle pain, tenderness or weakness was monitored. According to the severity, stop taking medicine and continue to use the same or reduced dose after improvement.  

Hyperuricemia: Monitor serum uric acid level regularly before and during treatment. According to the clinical indications, the treatment of uric acid lowering drugs was started. Pause and resume the same or reduced dose, or stop the drug permanently according to the severity.  

Bone fracture: timely evaluate patients with signs or symptoms of fracture (such as pain, change of mobility, deformity).  

Embryo-fetal toxicity: it can cause harm to the fetus. Inform women of the potential risks of reproductive potential to the fetus and use effective non-hormonal contraceptive methods.

[Adverse reaction of Augtyro]  

The most common adverse reactions (≥20%) are dizziness, taste disorder, peripheral neuropathy, constipation, dyspnea, ataxia, fatigue, cognitive impairment and myasthenia. 

Note: If there is any new packaging for drugs, the new packaging shall prevail. The above information comes from the Internet or translated by student volunteers in medical colleges and universities (if there are any mistakes or omissions, please help me to correct them). It is for internal discussion of medical staff only, without any basis for medication. Please consult the attending physician for specific medication guidelines.